TSH immunoassays employing scavenging reagents for cross-reacting endocrine glycoprotein hormone analogues

• US 9,068,994 B2
• Filed: 11/22/2013
• Issued: 06/30/2015
• Est. Priority Date: 05/27/2011
• Status: Active Grant

• Current Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories Incorporated)
• Inventors: Collier, G. Bruce, Omakor, John Emegbero
• Primary Examiner(s): Counts, Gary W
• Application Number:
  US14/087,286
• Publication Number:
  US 20140072989A1
• Time in Patent Office: 585 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: G01N 2333/59 Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• CPC Class Codes: G01N 33/53 Immunoassay; Biospecific binding assay; Materials therefor
• CPC Class Codes: G01N 33/54326 Magnetic particles
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
• CPC Class Codes: G01N 33/76 Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
• CPC Class Codes: Y10S 436/825 Pretreatment for removal of interfering factors from sample

Abstract

Thyroid Stimulating Hormone (TSH) immunoassays are performed using an ELISA sandwich assay that employs scavenging or sacrificial beads for reducing interference caused by cross-reacting endocrine glycoprotein hormone analogs such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).

Claims

1. A method for performing a thyroid stimulating hormone (TSH) immunoassay, the method comprising the steps of:

(a) inserting a fluid sample into a device comprising an immunosensor in a conduit, said immunosensor having a capture antibody to TSH;

(b) dissolving a signal antibody into said fluid sample;

(c) amending said fluid sample with scavenger beads for one or more of follicle stimulating hormone (FSH), luteinizing hormone (LH) and chorionic gonadotropin (CG);

(d) forming a sandwich complex on said immunosensor, said complex comprising said capture antibody, TSH, and said signal antibody;

(e) washing uncomplexed signal antibody from the immunosensor with a wash fluid; and

(f) detecting a signal associated with said complexed signal antibody,

wherein the scavenger beads are removed to a waste chamber downstream of the immunosensor prior to the detecting.

2. The method of claim 1, wherein said scavenger beads are magnetic, the process further comprising the step of retaining said scavenger beads in the waste chamber upon application of a magnet field.

3. The method of claim 1, wherein the scavenger beads comprise bead antibodies having a Kd that is less than about 0.15 nM for each of FSH, LH and CG, and a Kd(TSH) that is greater than about 250 nM.

4. The method of claim 1, wherein the scavenger beads comprise first scavenger beads for scavenging FSH, second scavenger beads for scavenging LH and third scavenger beads for scavenging CG.

5. The method of claim 1, wherein the capture antibody and the signal antibody each have a dissociation constant (Kd) for TSH of no greater than 0.15 nM.

6. The method of claim 1, wherein the capture antibody and the signal antibody each have a dissociation constant (Kd) for TSH of no greater than 0.15 nM, wherein the capture antibody Kd for follicle stimulating hormone (FSH), luteinizing hormone (LH) and chorionic gonadotropin (CG) is greater than 1000, greater than 1000 and greater than 500 nM, respectively, and wherein the signal antibody Kd for FSH, LH and CG are greater than 250, greater than 35 and greater than 35 nM, respectively.

7. The method of claim 1, wherein the capture antibody has a first Kd ratio, Kd(FSH):

Kd(TSH), of greater than 6000, and the signal antibody has a second Kd ratio, Kd(FSH);

Kd(TSH), of greater than 1500.

8. The method of claim 1, wherein the sandwich complex is formed by substantially non-sequential contact of said capture and signal antibodies with the fluid sample.

9. The method of claim 1, wherein the sandwich complex is formed without one or more intervening wash steps directed to ameliorating a cross reaction with one or more of FSH, LH and CG.

10. The method of claim 1, wherein the fluid sample is a diluted blood sample, an undiluted blood sample, a diluted plasma sample, or an undiluted plasma sample.

11. The method of claim 1, wherein the capture antibody comprises mouse monoclonal antibody 5409 and the signal antibody comprises mouse monoclonal antibody M94206.

12. The method of claim 1, wherein the capture antibody is covalently bound to a bead.

13. The method of claim 1, wherein the signal antibody is conjugated to a reporter molecule selected from the group consisting of alkaline phosphatase, horseradish peroxidase and a fluorescent moiety.

14. The method of claim 1, wherein the detecting step is electrochemical.

15. The method of claim 1, wherein the detecting step is optical.

16. The method of claim 1, comprising no more than one wash step to remove sample and unbound signal antibody from the capture antibody and where the wash fluid also contains substrate for a reporter molecule.

17. The method of claim 1, further comprising metering the fluid sample in a metering chamber to form a metered sample having a volume of from 1 to 500 μ

L.

18. The method of claim 1, further comprising bursting a wash fluid pouch, which is in fluid communication with the immunosensor, to release from 5 to 500 μ

L of wash fluid into said conduit.

19. The method of claim 1, further comprising forming a plurality of air segments in said wash fluid.

20. The method of claim 1, wherein the capture antibody and the signal antibody, respectively, are capable of binding to at least two different epitopes on a TSH-β

subunit of TSH.

21. The method of claim 1, wherein the capture antibody and the signal antibody are epitope-compatible antibodies.

22. The method of claim 1, wherein the capture antibody and signal antibody are selected from the following capture/signal antibody pairs 5409/M94206 and M94206/5409.